ClinicalTrials.gg
Status unknownNCT04121715Updated Oct 10, 2019

Fastigial Nucleus Stimulation for Coronary Heart Disease

An interventional study of Fastigial Nucleus Stimulation and Standard treatment in Coronary Disease, sponsored by Affiliated Hospital of North Sichuan Medical College. Status unknown at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2019-10-10.

Sponsored by Affiliated Hospital of North Sichuan Medical College · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2019), so the status shown — last known as Enrolling by invitation — may be out of date.

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jan 2019, registered Sep 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 224 studies in Coronary Disease with a site in China — 69 open to participants now, 78 under way, 3 of them phase 3. Coronary Disease · China.

Planned enrollment
76th of 142
200 · median 220
Started
2019
with 9 others
No phase
87 of 224
28 open now
Registered
108th of 224
by date

Among the 224 studies in Coronary Disease with a site in China, this one is the 76th largest by planned enrollment of the 142 interventional ones that give a count, is one of 10 that started in 2019, is one of 87 with no phase, and was the 108th registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 168 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

69 of the 224 studies in Coronary Disease with a site in China are open now. Recruiting first, the newest first:

64 more — sign in →

All 69 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 105 Coronary Disease studies recruiting now, 63 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 224 studies in Coronary Disease with a site in China, or all of them as a file.
02

Study summary

To observe the effects of fastigial nucleus stimulation on serum inflammation, oxidative stress related factors, cardiac autonomic function and prognosis in patients with coronary heart disease

Read the detailed description

In recent years, with the improvement of the material living standards of the investigators residents and the change of working lifestyle, the prevalence and mortality of coronary heart disease (CHD) in urban and rural residents in China have increased year by year. According to statistics, the number of patients with coronary heart disease in China is currently 11 million. Coronary heart disease has become a major health problem in China. At present, it is found that inflammatory reaction and oxidative stress factors are involved in the occurrence and development of coronary heart disease, and their indicators such as heart rate variability are related to the prognosis of coronary heart disease. Fastigial nucleus stimulation (FNS) has been widely used in the treatment of various diseases such as cerebrovascular disease, migraine, and eye diseases. The study found that FNS can reduce inflammatory cytokines and oxidative stress factors in ischemic myocardium and improve heart rate variability in rats with myocardial infarction. The aim of this study was to investigate whether FNS can improve the aforementioned indicators and clinical outcomes in patients with coronary heart disease.

03

Conditions studied

  • Coronary Disease

Browse trials for

Keywords

  • coronary heart disease
  • fastigial nucleus stimulation
  • inflammatory factors
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Coronary angiography was performed after admission, and coronary heart disease was diagnosed (coronary angiography showed at least one coronary artery with a diameter reduction of ≥50% from more than two different angles)
  • Patients and their families agreed and signed

Exclusion criteria

Exclusion Criteria:

  • Severe chronic heart failure, and \<30%
  • Body temperature > 38 ° C and / or combined with severe infection in any system
  • Severe liver and kidney dysfunction
  • Malignant tumor
  • diseases
  • High blood pressure and diabetes with severe comorbidities
  • Use of implantable electronic devices
  • Intracranial implanted vascular stents
  • Surface treatment electrode conductive materials Allergic or mastoid skin lesions
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    standard medication

    standard medication:Refer to the "Guidelines for Rational Use of Coronary Heart Diseases"

    Drug: Standard treatment

  • Experimental
    standard medication+fastigial nucleus stimulation

    1. fastigial nucleus stimulation:Use fastigial nucleus stimulation therapy device (Shanghai Renhe Medical Equipment Co., Ltd. CVFT series), each stimulation for 30 min, once a day, each patient treatment for about 20 days. 2. standard medication:Refer to the "Guidelines for Rational Use of Coronary Heart Diseases"

    Device: Fastigial Nucleus Stimulation · Drug: Standard treatment

Interventions

  • DeviceFastigial Nucleus Stimulation

    Select mode 3, frequency 136, intensity below 90, ratio 1.0-2.0, based on the patient's no discomfort. The main pole is attached to the bilateral mastoid, and the auxiliary pole is attached to the bilateral internal cave. Non-invasive introduction of bio-electricity into the cerebellar nucleus for stimulation

    Also known as: Standard treatment

  • DrugStandard treatment

    Refer to the "Guidelines for Rational Use of Coronary Heart Diseases".rational selection of antiplatelet drugs, statins, etc. according to the patient's condition

06

What researchers measure

Primary outcomes

  1. Observe the changes of serum IL-6 after treatment.

    Observe the changes of serum IL-6 levels(pg/ml)after treatment in the two groups of patients.

    Time frame: baseline,1month

  2. Observe the changes of serum hs-CRP after treatment.

    Observe the changes of serum hs-CRP levels(mg/l)after treatment in the two groups of patients.

    Time frame: baseline,1month

  3. Observe the changes of serum TNF-α after treatment.

    Observe the changes of serum TNF-α levels(pg/ml)after treatment in the two groups of patients.

    Time frame: baseline,1month

  4. Observe the changes of serum Lp-PLA2 after treatment.

    Observe the changes of serum Lp-PLA2 levels(ng/ml)after treatment in the two groups of patients.

    Time frame: baseline,1month

  5. Observe the changes of serum SOD(Superoxide dismutase) after treatment.

    Observe the changes of serum SOD levels(ng/ml)after treatment in the two groups of patients.

    Time frame: baseline,1month

  6. Observe the changes of serum GPX(Glutathione peroxidase) after treatment.

    Observe the changes of serum GPX levels(ng/ml)after treatment in the two groups of patients.

    Time frame: baseline,1month

  7. Observe the changes of serum MDA(Malondialdehyde) after treatment.

    Observe the changes of serum MDA levels(nmol/ml)after treatment in the two groups of patients.

    Time frame: baseline,1month

  8. Observe the changes of serum AOPP(Advanced oxidation protein product) after treatment.

    Observe the changes of serum AOPP levels(umol/l)after treatment in the two groups of patients.

    Time frame: baseline,1month

  9. Observe the changes of SDNN(Standard Deviation of the NN intervals) after treatment.

    Observe the changes of SDNN(ms)after treatment in the two groups of patients.

    Time frame: baseline,1month

  10. Observe the changes of SDANN(Standard Deviation of mean NN intervals in 5-minute recordings) after treatment.

    Observe the changes of SDANN(ms)after treatment in the two groups of patients.

    Time frame: baseline,1month

  11. Observe the changes of SDNN In(Average of the standard deviation of the NN interval every 5 minutes) after treatment.

    Observe the changes of SDNN In(ms)after treatment in the two groups of patients.

    Time frame: baseline,1month

  12. Observe the changes of rMSSD(square root of the mean squared differences of successive NN intervals) after treatment.

    Observe the changes of rMSSD(ms)after treatment in the two groups of patients.

    Time frame: baseline,1month

  13. Observe the changes of pNN50(Percentage of the difference between adjacent RR intervals >50ms ) after treatment.

    Observe the changes of pNN50(%)after treatment in the two groups of patients.

    Time frame: baseline,1month

Secondary outcomes

  1. Follow-up rate of major cardiovascular events

    The improvement of symptoms and the in-stent restenosis, myocardial infarction, readmission due to heart failure, and mortality were observed in the two groups after 12 months of discharge.

    Time frame: 12months

07

Study locations

1 site
  • The Third Hospital of Mianyang
    Mianyang, Sichuan 0816, China
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data for all primary and secondary outcome measures will be made available

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Data will be available within 6months of study completion

Access criteria: Data access requests will be reviewed by an external independent Reviwe Panel.Requestors will be required to sign a Data Access Agreement

Data sharing details ↗ · bethesda.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2019 (actual). Primary completion is estimated for Jan 2021, 24 months after the start.

Of 178 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 24 months is close to that.

Counting every sponsor, half of 200 studies reached it within 25 months; a quarter within 14 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2019
First posted
Oct 10, 2019
StartActual
Jan 16, 2019
Primary completionEst.
Jan 2021
CompletionEst.
Jan 2022
Last update
Oct 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04121715
Lead sponsor
Affiliated Hospital of North Sichuan Medical College
Collaborators
the Third Hospital of Mianyang
Responsible party
Sponsor
First posted
Oct 10, 2019
Start date
Jan 16, 2019
Primary completion
Jan 2021 (estimated)
Completion
Jan 2022 (estimated)
Last update
Oct 10, 2019

Study contacts

Runfeng Zhang, Ph.D
study chair · the Third Hospital of Mianyang
Wensong Li, master
principal investigator · the Third Hospital of Mianyang
Xin Lei, master
principal investigator · Affiliated Hospital of North Sichuan Medical College
Xiaoju Liu, master
principal investigator · Affiliated Hospital of North Sichuan Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion